Intranasal Oxytocin Phase 2B Trial Investigates Dysphagia, Appetite, and Behaviors in Pediatric Prader-Willi Syndrome
Background
Prader-Willi Syndrome (PWS) is a complex genetic disorder primarily caused by the loss of function of specific genes on chromosome 15. It is characterized by severe hyperphagia (insatiable appetite) leading to morbid obesity, developmental delays, intellectual disability, and distinctive behavioral challenges including temper outbursts and obsessive-compulsive traits. Early-life dysphagia (difficulty swallowing) and poor feeding are also common, paradoxically preceding the later onset of hyperphagia. Current management is largely supportive, focusing on strict dietary control and behavioral therapies, with no approved pharmacological treatments directly addressing the core symptoms of hyperphagia or behavioral dysregulation. The oxytocin system is implicated in social bonding, appetite regulation, and satiety, making it a promising target for PWS.
Study Design
This prospective, multicenter, randomized, double-blind, Phase 2B clinical study was designed to evaluate the effectiveness and safety of intranasal oxytocin in children and adolescents with Prader-Willi Syndrome (PWS). The trial planned to enroll approximately 24 PWS patients aged 2-17 years and 5 months. Participants were randomized to receive either intranasal oxytocin or placebo. The primary objectives were to investigate if intranasal oxytocin administration would improve dysphagia, alter appetite (specifically hyperphagia), and modify social skills and behaviors. Safety and tolerability of the intranasal oxytocin intervention were also key endpoints.
Results
The provided abstract describes the design and objectives of a Phase 2B clinical study investigating intranasal oxytocin for Prader-Willi Syndrome. It outlines the study's scope, participant population, and primary endpoints related to dysphagia, appetite, and behaviors, as well as safety. However, the abstract does not present any results or findings from the completed trial. Therefore, specific numerical data, statistical significance, or conclusions regarding the efficacy or safety of intranasal oxytocin in this cohort are not available within the provided information.
Why It Matters
If intranasal oxytocin proves effective in this Phase 2B trial, it could represent a significant breakthrough for individuals with Prader-Willi Syndrome (PWS). Currently, there are no approved pharmacological treatments that directly address the debilitating hyperphagia, dysphagia, or behavioral issues central to PWS. A successful intervention could dramatically improve the quality of life for patients and their families by potentially reducing the constant struggle with food, enhancing social integration, and mitigating challenging behaviors. The intranasal route is particularly appealing for pediatric populations, offering a non-invasive and potentially easier administration method compared to injections. Positive findings would pave the way for larger Phase 3 trials and potentially lead to the first targeted therapy for these core PWS symptoms, fundamentally altering the management paradigm.
prader-willi-syndrome
oxytocin
intranasal
pediatric
clinical-trial
dysphagia